Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index; 34 of the 71 sources its claims cite were checked for support.

Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial

Open access
Qin, Wenhui, Yang, Jun, Ni, Ying, Deng, Chao, Ruan, Qinjuan, Ruan, Jun, Zhou, Peng, Duan, Kai · 2024 · Endocrine

Abstract

AIM: Tirzepatide, a newly developed dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has received approval for treating type 2 diabetes (T2D) and is currently being studied for its potential in long-term weight control. We aim to explore the safety and efficacy of once-weekly subcutaneous tirzepatide for weight loss in T2D or obese patients. METHODS: A comprehensive search was performed on various databases including PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov from inception up to April 29, 2024, to identify randomized controlled trials (RCTs) that assessed the efficacy of once-weekly tirzepatide compared to a placebo in adults with or without T2D. The mean difference (MD) and risk ratio (RR) were calculated for continuous and dichotomous outcomes, respectively. The risk of bias was evaluated using the RoB-2 tool (Cochrane), while the statistical analysis was conducted utilizing RevMan 5.4.1 software. RESULTS: Seven RCTs comprising 4795 individuals ranging from 12 to 72 weeks were identified. Compared to the placebo group, tirzepatide at doses of 5, 10, and 15 mg demonstrated significant dose-dependent weight loss. The mean difference (MD) in the percentage change in body weight (BW) was -8.07% (95% CI -11.01, -5.13; p < 0.00001), -10.79% (95% CI -13.86, -7.71; p < 0.00001), and -11.83% (95% CI -14.52, -9.14; p < 0.00001), respectively. Additionally, the MD in the absolute change in BW was -7.5 kg (95% CI -10.9, -4.1; p < 0.0001), -11.0 kg (95% CI -16.9, -5.2; p = 0.0002), and -11.5 kg (95% CI -16.2, -6.7; p < 0.00001), for the 5, 10, and 15 mg doses, respectively. All three doses of tirzepatide also significantly reduced body mass index and waist circumference. Furthermore, it led to a greater percentage of patients experiencing weight loss exceeding 5, 10, 15, 20, and 25%. Moreover, tirzepatide showed great success in reducing blood pressure, blood sugar levels, and lipid profiles. In terms of safety, gastrointestinal side effects were the most frequently reported adverse events in all three doses of tirzepatide groups, which were generally mild-to-moderate and transient. CONCLUSION: Tirzepatide treatment could lead to remarkable and sustained weight loss that is well-tolerated and safe, representing a novel and valuable therapeutic strategy for long-term weight management.

Overview

CoChat Summary

TL;DR

This updated meta-analysis of 7 randomized controlled trials (4,795 participants) found that once-weekly tirzepatide produced dose-dependent weight loss versus placebo and improved several cardiometabolic markers. The main tradeoff was more gastrointestinal adverse events, while serious adverse events and hypoglycemia were not increased.

Key findings

  • Across 7 RCTs (4,795 participants; 12–72 weeks), tirzepatide reduced percentage body weight versus placebo by −8.07% with 5 mg, −10.79% with 10 mg, and −11.83% with 15 mg, all p < 0.00001.
  • Absolute body weight change versus placebo was −7.5 kg, −11.0 kg, and −11.5 kg for 5, 10, and 15 mg, respectively.
  • More participants achieved clinically meaningful weight loss with tirzepatide: ≥5% loss was 75.8%, 81.6%, and 84.3% for 5, 10, and 15 mg, versus 26.4%/27.9% with placebo; ≥20% loss in SURMOUNT-1 and SURMOUNT-2 reached 30%, 40.7%, and 48.1% for 5, 10, and 15 mg, versus 3.1%/2.4% with placebo; ≥25% loss was 15.2%, 24.6%, and 29.3% versus 1.6%/1.1%.
  • Tirzepatide also improved BMI, waist circumference, SBP, HbA1c, fasting plasma glucose, and fasting lipids; gastrointestinal adverse events were the most common safety issue, with adverse events more frequent than placebo, but serious adverse events and hypoglycemia were not significantly different.

Methods

  • Systematic review and meta-analysis conducted according to PRISMA 2020, with PROSPERO registration (CRD42023458081).
  • Searched PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov up to April 29, 2024 for English-language RCTs in adults with or without T2D comparing once-weekly subcutaneous tirzepatide (5/10/15 mg) with placebo.
  • Used mean differences for continuous outcomes and risk ratios for dichotomous outcomes; risk of bias was assessed with RoB-2, certainty with GRADE, and all pooled analyses used a random-effects model in RevMan 5.4.1.

Limitations

  • The paper states it relied on published, study-level data rather than real-world patient data, and all included RCTs were supported by the pharmaceutical industry, which may overestimate benefit due to reporting bias.
  • It states the effect of differing exercise and dietary regimens could not be quantified or assessed, and that most studies included selected diabetic populations rather than general non-diabetic populations.
  • It states sample size and the number of included studies were limited, and that most research came from North/South America, Europe, and Japan with primarily Caucasian participants, limiting generalizability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s12020-024-03896-z

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 2020 PRISMA flow diagram of the study selection
Fig. 1 2020 PRISMA flow diagram of the study selectionCC BY · PubMed Central
Fig. 2 Comparison of three doses of tirzepatide versus placebo for percent weight change from baseline (a) and absolute weight change from baseline, in kg (b)
Fig. 2 Comparison of three doses of tirzepatide versus placebo for percent weight change from baseline (a) and absolute weight change from baseline, in kg (b)CC BY · PubMed Central
Fig. 3 Effect of three doses of tirzepatide on achieving weight loss goals of ≥5% from baseline compared to placebo
Fig. 3 Effect of three doses of tirzepatide on achieving weight loss goals of ≥5% from baseline compared to placeboCC BY · PubMed Central
Fig. 4 Comparison of three doses of tirzepatide versus placebo for BMI change from baseline, in kg/m2 (a) and WC change from baseline, in cm (b)
Fig. 4 Comparison of three doses of tirzepatide versus placebo for BMI change from baseline, in kg/m2 (a) and WC change from baseline, in cm (b)CC BY · PubMed Central

Verification

Claims the paper makes

23 Valid · 2 Not valid · 14 Not checked · 106 Own results and interpretations

88 more claims · 7 with their cited sources checked

Create a free account to see all 145 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 16
  • It may state two separate claims as one. 41

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 48 references

Research works printed but not linked: 1

  1. H. Patel, K. Khunti, H.W. Rodbard et al. Tirzepatide-induced weight loss in type 2 diabetes is independent of nausea, vomiting, or diarrhoea. Diabetologia 65(abstr 568), 290–91 (2022).

Cited by

See all 55

Metadata

Authors
Qin, W., Yang, J., Ni, Y., Deng, C., Ruan, Q., Ruan, J., Zhou, P., & Duan, K.
Affiliations
  • Huazhong University of Science and Technology (CN)
  • Wuhan Union Hospital (CN)
Corresponding author
  • Zhou, Peng
  • Duan, Kai
Venue
Endocrine
Published
2024-06-08
Volume
86
Issue
1
Pages
70-84
ISSN
  • 0969-711X (ISSN-L)
  • 1559-0100
OpenAlex
W4399462567
Cited by
55
References
48
Citations by year
2026: 21 · 2025: 28 · 2024: 5
FWCI
5.34
Type
journal article
Language
en
Open access
Licence
Locations
  • Endocrine (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
tirzepatide, weight loss, obesity, type 2 diabetes, GIP/GLP-1 receptor agonist, body weight, adverse events, drug safety
MeSH terms
Glucagon-Like Peptide-2 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial. https://app.cochat.ai/papers/10.1007/s12020-024-03896-z
The paper
Qin, W., Yang, J., Ni, Y., Deng, C., Ruan, Q., Ruan, J., Zhou, P., & Duan, K. (2024). Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial. Endocrine. https://doi.org/10.1007/s12020-024-03896-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.